Taysha Gene Therapies is a pre-commercial gene therapy company with 78% analyst-implied upside, a 2.3x volume surge on recent upward moves, and a strongly bullish technical breakout — but its cash-burning status, below-quality-floor metrics, and extreme put/call ratio of 30.20 reflect the high binary risk of a development-stage biotech.
Thesis pillars
- Large Analyst Upside Gene Therapy→Stable
- Cash Burn Clinical Stage Risk→Stable
- Extreme Put Call Ratio Binary Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $6.58: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality.
Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV9-based gene therapies for monogenic central nervous system diseases, with TSHA-102 — its sole product candidate in clinical development — targeting Rett syndrome via a one-time intrathecal gene... Read more
Sell if holding. Engine safety override at $6.58: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Score 5.3/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Taysha Gene Therapies, Inc.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies' entire near-term prospects rest on TSHA-102, its sole clinical-stage product candidate, a one-time AAV9 gene therapy delivered intrathecally for Rett syndrome, which affects an estimated 15,000 to 20,000 patients across the U.S., EU, and UK. In Part A of the REVEAL Phase 1/2 trials, all 10 evaluable patients gained or regained at least one developmental milestone as of the May 19, 2025 data cutoff, with no treatment-related serious adverse events across 12 dosed patients through March 2026.
Taysha has no approved products and generates no product revenue, funding TSHA-102's development entirely through equity and debt financing while relying exclusively on its collaboration with UT Southwestern for preclinical research, IND-enabling studies, and near-term pipeline discovery. The company has aligned with the FDA on Chemistry, Manufacturing and Controls requirements and a Process Performance Qualification campaign, planned to begin in the second quarter of 2026, to validate the commercial manufacturing process ahead of a planned biologics license application. TSHA-102 carries Breakthrough Therapy, Regenerative Medicine Advanced Therapy, Fast Track, and orphan drug designations from the FDA, orphan drug designation from the European Commission, and Innovative Licensing and Access Pathway designation from the U.K.'s medicines regulator, designations intended to expedite development and review but that do not guarantee eventual approval.
Show full overview
The REVEAL pivotal trial's entire statistical case for a BLA rests on a single-arm design with no concurrent control: success requires at least 5 of 15 enrolled patients, a 33% response rate, to gain or regain a developmental milestone, compared to a natural-history-derived null hypothesis of just 6.7%, or roughly 1 of 15 patients, doing so without treatment. A 6-month interim analysis, rather than the full trial readout, may serve as the basis for the BLA submission, a pathway that could accelerate filing by an estimated two quarters if the interim data holds up, but that also means Taysha's near-term regulatory and commercial timeline hinges on results from a small, single-arm cohort rather than a larger controlled trial.
See also: Healthcare · Biotechnology
From Taysha Gene Therapies, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-07Recent Developments — Taysha Gene Therapies, Inc.
Latest news
- NEWS Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target — benzinga Jul 2, 2026 positive
- NEWS Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga Jun 30, 2026 neutral
- NEWS Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15 — benzinga Jun 30, 2026 positive
- NEWS H.B. Fuller, Trip.com, Hertz Global And Other Big Stocks Moving Lower In Thursday Pre-Market Session — benzinga Jun 25, 2026 neutral
- NEWS Why Micron Technology Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket — benzinga Jun 25, 2026 neutral
Generated 2026-07-07T09:31:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineTSHA-10210-K Item 1A: 'TSHA-102 is currently our sole product candidate in clinical development.'
- HIGHcounterpartyUT Southwestern10-K Item 1A: 'We currently rely exclusively on our collaboration with UT Southwestern for our preclinical research and development programs'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $6.58: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 5.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $5.93. Score 5.3/10, moderate confidence.
Take-profit target: $11.31 (+77.3% upside). Prior stop was $5.93. Stop-loss: $5.93.
Concentration risk — Pipeline: TSHA-102; Concentration risk — Counterparty: UT Southwestern; Quality below floor (3.3 < 4.0).
Taysha Gene Therapies, Inc. trades at a P/E of N/A (forward -15.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover TSHA with a consensus score of 4.3/5. Average price target: $13.
What does Taysha Gene Therapies, Inc. do?Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV9-based gene therapies for monogenic...
Taysha Gene Therapies is a clinical-stage biotechnology company developing AAV9-based gene therapies for monogenic central nervous system diseases, with TSHA-102 — its sole product candidate in clinical development — targeting Rett syndrome via a one-time intrathecal gene therapy. In Part A of the REVEAL Phase 1/2 trials, all 10 evaluable patients gained or regained at least one developmental milestone as of the May 2025 data cutoff, and the company has since dosed patients in the pivotal REVEAL trial (15 patients aged 6 to <22) and the ASPIRE trial (3 patients aged 2 to <4), aiming for a BLA